Analysis of RET proto-oncogene abnormalities in patients with MEN 2A, MEN 2B, familial or sporadic medullary thyroid carcinoma

1998 ◽  
Vol 21 (6) ◽  
pp. 358-364 ◽  
Author(s):  
E. Chiefari ◽  
D. Russo ◽  
D. Giuffrida ◽  
G. A. Zampa ◽  
D. Meringolo ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid ◽  
Men 2B ◽  
Men 2A

Medullary thyroid carcinoma: Including MEN 2A and MEN 2B syndromes

2005 ◽  
Vol 89 (3) ◽  
pp. 122-129 ◽  
Author(s):  
Frank J. Quayle ◽  
Jeffrey F. Moley
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Medullary Thyroid ◽  
Men 2B ◽  
Men 2A

scholarly journals Rapid, nonradioactive screening for mutations in exons 10, 11, and 16 of the RET protooncogene associated with inherited medullary thyroid carcinoma

1997 ◽  
Vol 43 (3) ◽  
pp. 453-457 ◽  
Author(s):  
Mark Siegelman ◽  
Ajay Mohabeer ◽  
Thomas J Fahey ◽  
Gail Tomlinson ◽  
Chris Mayambala ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Mutation Analysis ◽  
Medullary Thyroid ◽  
Ret Protooncogene ◽  
Highly Sensitive ◽  
Detection Of Mutations ◽  
Cancer Syndromes ◽  
Men 2B ◽  
Men 2A

Abstract Germline mutations in exons 10, 11, and 16 of the RET protooncogene are associated with the heritable cancer syndromes multiple endocrine neoplasia (MEN) type 2A, familial medullary thyroid carcinoma (FMTC), and MEN type 2B. Nonradioactive mutation analysis with nondenaturing Phastgels® and the Phast System™ was performed on DNA amplified by the polymerase chain reaction from exons 10, 11, and 16 of the RET protooncogene from patients with MEN 2A, MEN 2B, or FMTC. The analysis requires ∼45–90 min for electrophoresis and 35 min for staining. This assay detected 20 of 21 different mutations that represented ∼90% of all known mutations associated with these lesions. A rare silent polymorphism within exon 10 was also detected. This form of mutation analysis provides simple, rapid, and highly sensitive nonradioactive detection of mutations known to be associated with MEN 2A, FMTC, and MEN 2B.

scholarly journals Additive effect of RET polymorphisms on sporadic medullary thyroid carcinoma susceptibility and tumor aggressiveness

2012 ◽  
Vol 166 (5) ◽  
pp. 847-854 ◽  
Author(s):  
L. Ceolin ◽  
D. R. Siqueira ◽  
C. V. Ferreira ◽  
M. Romitti ◽  
S. C. Maia ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Additive Effect ◽  
Tumor Aggressiveness ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid

New Multiple Somatic Mutations in the RET Proto-oncogene Associated with a Sporadic Medullary Thyroid Carcinoma

Thyroid ◽  
2006 ◽  
Vol 16 (3) ◽  
pp. 311-316 ◽  
Author(s):  
Š. Dvořáková ◽  
E. Václavíková ◽  
V. Sýkorová ◽  
J. Dušková ◽  
P. Vlček ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Somatic Mutations ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid

Analysis of alternative mechanisms for RET gene activation in hereditary and sporadic Medullary Thyroid Carcinoma

2010 ◽  
Vol 203 (1) ◽  
pp. 50
Author(s):  
Ciampi Raffaele ◽  
Romei Cristina ◽  
Vivaldi Agnese ◽  
Cosci Barbara ◽  
Tacito Alessia ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Gene Activation ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid ◽  
Ret Gene

scholarly journals Risk Factors for Lateral Lymph Node Metastases in Patients With Sporadic Medullary Thyroid Carcinoma

2020 ◽  
Vol 19 ◽  
pp. 153303382096208
Author(s):  
Xin Wu ◽  
Binglu Li ◽  
Chaoji Zheng ◽  
Wei Liu ◽  
Tao Hong ◽  
...  
Keyword(s):  
Lymph Node ◽  
Thyroid Carcinoma ◽  
Medullary Thyroid Carcinoma ◽  
Lymph Node Metastases ◽  
Lateral Neck ◽  
Lateral Neck Dissection ◽  
Lateral Lymph Node ◽  
Sporadic Medullary Thyroid Carcinoma ◽  
Medullary Thyroid ◽  
Node Metastases

Purpose: Medullary thyroid carcinoma is a rare endocrine malignancy; 75% of patients with this disease have sporadic medullary thyroid carcinoma. While surgery is the only curative treatment, the benefit of prophylactic lateral neck dissection is unclear. This study aimed to analyze the clinicopathological risk factors associated with lateral lymph node metastases and determine the indication for prophylactic lateral neck dissection in patients with sporadic medullary thyroid carcinoma. Methods: The medical records of patients with medullary thyroid carcinoma who were treated at our hospital between January 2002 and January 2020 were retrospectively reviewed; a database of their demographic characteristics, test results, and pathological information was constructed. The relationship between lateral lymph node metastases and clinicopathologic sporadic medullary thyroid carcinoma features were analyzed using univariate and multivariate analyses. Results: Overall, 125 patients with sporadic medullary thyroid carcinoma were included; 47.2% and 39.2% had confirmed central and lateral lymph node metastases, respectively. Univariate and multivariate analyses identified 2 independent factors associated with lateral lymph node metastases: positive central lymph node metastases (odds ratio = 9.764, 95% confidence interval: 2.610–36.523; p = 0.001) and positive lateral lymph nodes on ultrasonography (odds ratio = 101.747, 95% confidence interval: 14.666–705.869; p < 0.001). Conclusion: Medullary thyroid carcinoma is a rare endocrine malignancy. Lymph node metastases are common in patients with sporadic medullary thyroid carcinoma. Prophylactic lateral neck dissection is recommended for patients who exhibit positive central lymph node metastases and/or positive lateral lymph nodes on ultrasonography.

Sign in / Sign up

Export Citation Format

Share Document